Cingulate inc.CINGW.US Overview

US StockHealthcare

(No presentation for CINGW)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock SentimentalTradingView Chart

CINGW Overall Performance

CINGW AI Analysis & Strategy

CINGW Recent Performance

-0.84%

Cingulate inc.

0.81%

Avg of Sector

-1.14%

S&P500

CINGW PowerScanner

CINGW Key Information

CINGW Valuation Metrics

CINGW Earnings Table

CINGW Profile

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.